Annual CFO
-$6.58 M
+$2.24 M+25.35%
December 1, 2023
Summary
- As of February 7, 2025, XRTX annual cash flow from operations is -$6.58 million, with the most recent change of +$2.24 million (+25.35%) on December 1, 2023.
- During the last 3 years, XRTX annual CFO has fallen by -$6.01 million (-1052.52%).
- XRTX annual CFO is now -9180.28% below its all-time high of $72.50 thousand, reached on December 1, 2017.
Performance
XRTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$751.90 K
-$15.40 K-2.09%
September 1, 2024
Summary
- As of February 7, 2025, XRTX quarterly cash flow from operations is -$751.90 thousand, with the most recent change of -$15.40 thousand (-2.09%) on September 1, 2024.
- Over the past year, XRTX quarterly CFO has increased by +$546.20 thousand (+42.08%).
- XRTX quarterly CFO is now -165.57% below its all-time high of $1.15 million, reached on December 1, 2020.
Performance
XRTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$4.09 M
+$318.80 K+7.23%
September 1, 2024
Summary
- As of February 7, 2025, XRTX TTM cash flow from operations is -$4.09 million, with the most recent change of +$318.80 thousand (+7.23%) on September 1, 2024.
- Over the past year, XRTX TTM CFO has increased by +$2.49 million (+37.87%).
- XRTX TTM CFO is now -146185.71% below its all-time high of $2800.00, reached on August 1, 2014.
Performance
XRTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
XRTX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +25.4% | +42.1% | +37.9% |
| 3 y3 years | -1052.5% | +69.7% | +54.3% |
| 5 y5 years | -476.5% | +69.7% | +54.3% |
XRTX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -38.5% | +25.4% | -2.1% | +79.2% | at high | +54.4% |
| 5 y | 5-year | -3344.9% | +25.4% | -165.6% | +79.2% | -4099.6% | +54.4% |
| alltime | all time | -9180.3% | +25.4% | -165.6% | +79.2% | <-9999.0% | +54.4% |
XORTX Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$751.90 K(+2.1%) | -$4.09 M(-7.2%) |
| Jun 2024 | - | -$736.50 K(-43.5%) | -$4.41 M(-18.4%) |
| Mar 2024 | - | -$1.30 M(+0.4%) | -$5.40 M(-17.9%) |
| Dec 2023 | -$6.58 M(-25.3%) | -$1.30 M(+21.2%) | -$6.58 M(-26.0%) |
| Sep 2023 | - | -$1.07 M(-38.1%) | -$8.90 M(+1.2%) |
| Jun 2023 | - | -$1.73 M(-30.4%) | -$8.80 M(-1.7%) |
| Mar 2023 | - | -$2.49 M(-31.2%) | -$8.95 M(-0.2%) |
| Dec 2022 | -$8.82 M(+85.5%) | -$3.61 M(+273.5%) | -$8.96 M(+5.5%) |
| Sep 2022 | - | -$967.60 K(-48.5%) | -$8.50 M(+12.6%) |
| Jun 2022 | - | -$1.88 M(-25.0%) | -$7.54 M(+18.3%) |
| Mar 2022 | - | -$2.50 M(-20.5%) | -$6.38 M(+32.8%) |
| Dec 2021 | -$4.75 M(+732.4%) | - | - |
| Dec 2021 | - | -$3.15 M(>+9900.0%) | -$4.80 M(+847.9%) |
| Sep 2021 | - | -$14.80 K(-97.9%) | -$506.50 K(-17.5%) |
| Jun 2021 | - | -$711.90 K(-23.2%) | -$613.60 K(+530.0%) |
| Mar 2021 | - | -$926.60 K(-180.8%) | -$97.40 K(-83.0%) |
| Dec 2020 | -$571.20 K(+198.9%) | $1.15 M(-1040.8%) | -$571.30 K(-68.3%) |
| Sep 2020 | - | -$121.90 K(-37.7%) | -$1.80 M(+7.9%) |
| Jun 2020 | - | -$195.70 K(-86.0%) | -$1.67 M(+10.9%) |
| Mar 2020 | - | -$1.40 M(+1612.1%) | -$1.50 M(+686.9%) |
| Dec 2019 | -$191.10 K | -$81.80 K(-871.7%) | -$191.10 K(+33.0%) |
| Sep 2019 | - | $10.60 K(-133.0%) | -$143.70 K(-55.8%) |
| Jun 2019 | - | -$32.10 K(-63.4%) | -$325.20 K(-33.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$87.80 K(+155.2%) | -$489.00 K(-57.2%) |
| Dec 2018 | -$1.14 M(-1675.0%) | -$34.40 K(-79.9%) | -$1.14 M(+0.6%) |
| Sep 2018 | - | -$170.90 K(-12.8%) | -$1.14 M(+10.9%) |
| Jun 2018 | - | -$195.90 K(-73.6%) | -$1.02 M(+18.2%) |
| Mar 2018 | - | -$740.70 K(+2583.7%) | -$866.50 K(+448.4%) |
| Dec 2017 | $72.50 K(-151.3%) | - | - |
| Nov 2017 | - | -$27.60 K(-53.7%) | -$158.00 K(-27.3%) |
| Aug 2017 | - | -$59.60 K(+54.4%) | -$217.30 K(+33.8%) |
| May 2017 | - | -$38.60 K(+642.3%) | -$162.40 K(+10.9%) |
| Mar 2017 | - | -$5200.00(-80.7%) | -$146.40 K(+3.7%) |
| Feb 2017 | -$141.30 K(+76.2%) | -$27.00 K(-68.9%) | -$141.20 K(+11.0%) |
| Dec 2016 | -$80.20 K(-37.6%) | - | - |
| Nov 2016 | - | -$86.90 K(+1748.9%) | -$127.20 K(-15.2%) |
| Aug 2016 | - | -$4700.00(-79.2%) | -$150.00 K(-0.6%) |
| May 2016 | - | -$22.60 K(+73.8%) | -$150.90 K(+17.3%) |
| Feb 2016 | -$128.60 K(+50.6%) | -$13.00 K(-88.1%) | -$128.60 K(-36.8%) |
| Nov 2015 | - | -$109.70 K(+1858.9%) | -$203.60 K(+116.4%) |
| Aug 2015 | - | -$5600.00(+1766.7%) | -$94.10 K(+12.4%) |
| May 2015 | - | -$300.00(-99.7%) | -$83.70 K(-2.0%) |
| Feb 2015 | -$85.40 K | -$88.00 K(>+9900.0%) | -$85.40 K(-3384.6%) |
| Nov 2014 | - | -$200.00(-104.2%) | $2600.00(-7.1%) |
| Aug 2014 | - | $4800.00(-340.0%) | $2800.00(-240.0%) |
| May 2014 | - | -$2000.00 | -$2000.00 |
FAQ
- What is XORTX Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for XORTX Therapeutics?
- What is XORTX Therapeutics annual CFO year-on-year change?
- What is XORTX Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for XORTX Therapeutics?
- What is XORTX Therapeutics quarterly CFO year-on-year change?
- What is XORTX Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for XORTX Therapeutics?
- What is XORTX Therapeutics TTM CFO year-on-year change?
What is XORTX Therapeutics annual cash flow from operations?
The current annual CFO of XRTX is -$6.58 M
What is the all time high annual CFO for XORTX Therapeutics?
XORTX Therapeutics all-time high annual cash flow from operations is $72.50 K
What is XORTX Therapeutics annual CFO year-on-year change?
Over the past year, XRTX annual cash flow from operations has changed by +$2.24 M (+25.35%)
What is XORTX Therapeutics quarterly cash flow from operations?
The current quarterly CFO of XRTX is -$751.90 K
What is the all time high quarterly CFO for XORTX Therapeutics?
XORTX Therapeutics all-time high quarterly cash flow from operations is $1.15 M
What is XORTX Therapeutics quarterly CFO year-on-year change?
Over the past year, XRTX quarterly cash flow from operations has changed by +$546.20 K (+42.08%)
What is XORTX Therapeutics TTM cash flow from operations?
The current TTM CFO of XRTX is -$4.09 M
What is the all time high TTM CFO for XORTX Therapeutics?
XORTX Therapeutics all-time high TTM cash flow from operations is $2800.00
What is XORTX Therapeutics TTM CFO year-on-year change?
Over the past year, XRTX TTM cash flow from operations has changed by +$2.49 M (+37.87%)